With the emergence of increased GLP-1 use and alternative PBM models, Morgan Lee, PhD, MPH, CPH, and Scott Halperin, PharmD, joined Drug Topics to discuss current trends in drug benefit design.
Scott Halperin, PharmD
Advertisement
Articles by Scott Halperin, PharmD
Pharmaceutical Strategies Group experts joined Drug Topics to discuss the role GLP-1s play in drug benefit design.
Morgan Lee, PhD, MPH, CPH, and Scott Halperin, PharmD, from the Pharmaceutical Strategies Group, discuss how the role of PBMs in plan design is evolving.
Morgan Lee, PhD, MPH, CPH, and Scott Halperin, PharmD, from the Pharmaceutical Strategies Group, discuss the 2025 Trends in Drug Benefit Design Report and how it will impact pharmacists.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Drug Topics
1
Pharmacists Must Guide Peptide Talks Pending FDA Action | NCPA 2026
2
FAQ: Scaling Pharmacy Services Through GLP-1 Care | NCPA 2026
3
Pharmacists Improve Access, Safe Use of Obesity Medications
4
PBM Underpayment Persists as Cost-Plus Brings New Strain | NCPA 2026
5